Nuron secures option, license deal to develop NU400 for RRMS
Posted: Fri May 27, 2011 1:36 am
Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' site-specific TheraPEG™ PEGylation technology to develop NU400, a long-acting version of Nuron's proprietary recombinant human interferon beta-1b (NU100).
PEGylating NU100 can also potentially improve other properties including its solubility, stability and safety profile. NU100 is poised to enter Phase 3 clinical studies in 2011 based on recent positive regulatory advice from the European Medicines Agency (EMEA).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2872